OptiScanner is the first-of-its-kind bedside blood monitoring platform that provides plasma-based, automated monitoring of ICU patients’ glucose levels. The OptiScanner 5000 directly measures plasma glucose levels using an integrated blood centrifuge and spectrometer to help avoid dangerous glycemic variations and assist clinicians in achieving the right level of glucose control. It is well-proven that critically ill patients often suffer from stress-induced hyperglycemia, glycemic variability, or hypoglycemia, which has been associated with increased morbidity and mortality in both patients with diabetes and those without.
Healthcare providers can use the OptiScanner to track a patient’s glucose in real-time. Trending data allows the clinicians to detect changes earlier and make proactive decisions to help patients stay within the targeted glycemic range. It is plasma-based so It directly measures glucose levels in blood plasma. There is no calibrations and the mid-infrared spectroscopy never requires time-consuming calibration, unlike reagent-based technologies. It automatically measures and trends glucose levels every 15 minutes, delivering an early warning system that supports proactive intervention. The OptiScanner 5000 uses a proprietary patient connector as an interface between the patient’s IV line and the unit. The system draws a small amount of patient blood (only consuming 0.15 mL per draw) every 15 minutes, separates the blood plasma in a micro-centrifuge, and then reads the plasma sample with a mid-range infrared spectrometer. Within a few minutes of the blood draw, a reading is displayed on the front of the OptiScanner. This seamless connection with the distal port of any vascular access line eliminates the need for heparin delivery to the patient and one cartridge can be used for up to 3 days. OptiScan Biomedical is expanding the OptiScanner platform to include additional metabolic and hemodynamic analytes using the same sample of blood.